Abstract 167P
Background
HCC is the most common primary liver malignancy and cause of cancer-related death worldwide and in Bangladesh. It occurs more often in males than females. The incidence of HCC continues to escalate due to HBV, HCV infection, non-alcoholic fatty liver disease (NAFLD). HBV and HCV are also important risk factors for developing chronic liver disease (CLD) and HCC.
Methods
The study was an observational study. All HCC patients in National Institute of Cancer Research and Hospital and Shaheed Suhrawardy Medical College Hospital, Dhaka, Bangladesh from Jan.2010 to Dec.2019 were included. Clinical information and demographic profiles were recorded from departmental documents and retrospectively studied. Patients were arranged as Birch Classification.
Results
Of 1028 patients, 752 (73.15%) were male and 276 (26.85%) were female; M:F was 2.72:1. The average age of HCC onset was 57.9, lowest 23 and highest was 90. The leading age group was ≥60 years, 315 (30.64%) followed by 50-59 year 256 (24.90%), 40-49 year 254 (24.71%). 106 (10.31%) patients presented with metastasis. 688 (66.92%) patients had habitual problems. 478 (46.50%) patients were infected with HBV, 56 (5.45%) were infected with HCV, 632 (61.48%) were suffering from CLD, 180 (17.51%) from NAFLD and only 48 (4.46%) had family histories of malignancy. 240 (23.36%) patients presented with comorbidities. Only 13 (1.26%) were vaccinated against HBV and none had attended for HCC screening. Most patients were poor, 724 (70.43%%) and 683 (66.44%) were illiterate. The leading profession was farmer, 408 (39.69%), followed by housewife, 223 (21.70%).The leading symptom was pain, 348 (33.85%) followed by anorexia, 327 (31.81%), right hypochondriac heaviness, 284 (27.63%). 267 (25.97%) patients presented with impaired liver function, and 339 (32.97%) presented with high alfa feto protein (AFP). 521 (50.68%) patients were on symptomatic treatment prior to attending an oncologist.
Conclusions
HCC is an aggressive cancer and concomitant liver dysfunction with advanced disease impedes curative therapies. HCC can be prevented if appropriate measures are taken, such as HBV vaccination, screening of blood products, use of safe injection practices, treatment and education of alcoholics and drug users.
Clinical trial identification
Editorial acknowledgement
Department of Medical oncology of Shaheed suhrawardy medical college hospital and National Institute of cancer research & hospital
Legal entity responsible for the study
Abdullah Al Mamun Khan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session